This article is part of “Innovations In: Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. The global burden of chronic kidney disease ...

With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population of patients with chronic kidney disease (CKD). Kerendia, also known as ...

Finerenone significantly improves eGFR slope in patients with nondiabetic chronic kidney disease, suggesting a slowed progression of renal decline. Topline results were announced from a phase 3 trial ...

Reducing how much sodium and salt you consume can help you manage chronic kidney disease (CKD). Although your body needs sodium to function properly, excessive sodium intake can worsen CKD and cause ...

Please provide your email address to receive an email when new articles are posted on . Risks for cognitive impairment increased with more advanced CKD stages. Associations were strongest for higher ...

More than one in seven adults in the United States are estimated to have chronic kidney disease (CKD), a disease caused by diabetes, hypertension, or other health care conditions that cause severe ...

CKD is a significant nontraditional risk factor for CVD, affecting 10% of the global population and increasing cardiovascular morbidity and mortality. Cardiovascular risk in CKD patients begins early ...

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program. The alliance ...

Chronic kidney disease (CKD) affects people across the globe and often progresses to the point where patients rely on routine dialysis to survive. Although the condition is widespread and serious, ...

Chronic kidney disease (CKD) was the ninth-leading cause of death worldwide in 2023, accounting for 1.48 million deaths. Its global age-standardized prevalence increased from 3.5% to 14.2%, according ...